ArticleDiscover oncology2025
Exploration of oxidative stress-related molecular signature for clear cell renal cell carcinoma.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Tumorigenesis and progression can be promoted by oxidative stress. However, there is a lack of evidences regarding the expression profiles of oxidative stress-associated genes (OSRGs) in the tumorigenesis and development of clear cell renal cell carcinoma (ccRCC). In the present study, we performed transcriptome analyses on 611 samples from TCGA database and 645 samples from GEO database. Using unsupervised consensus clustering method, we identified two oxidative stress patten (OS_A and OS_B) according to the 278 differentially expressed OSRGs in both TCGA and GEO databases. We further evaluated the prognostic significance, tumor immune microenvironment, and related pathways between two oxidative stress patterns. Subsequently, we identified 7 prognostic OSRGs (CCL7, CDCA3, CRABP2, IRF6, MAGEA4, PLG, SAA1) from both two patterns to incorporate into an OSRG-based prognostic model, and developed a prognostic risk scoring system (OS_score) to distinguish patients with high-risk and poor prognosis. We then develop a miRNA-OSRG regulatory network based on differentially expressed miRNAs and prognostic OSRGs genes, and identify the correlation between OS_score and tumor mutation burden (TMB). Patients from high-risk groups performed an increased expression of immune checkpoint inhibitor (ICI) genes, including PD-1, CTLA-4, B7H3, B7H4, and were more likely to respond to anti-PD-1 immunotherapy. Correlation analysis revealed that AKT inhibitor VIII, EHT-1864 and AS601245 might provide benefits for patients with high OS_score. In conclusion, we conducted a thorough analysis of the expression profiles of OSRGs in ccRCC, culminating in the development of a robust prognostic model and scoring system aimed at accurately predicting survival outcomes for ccRCC patients. This endeavor has the potential to yield novel insights into redox biology and to advance the current treatment strategies for ccRCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.